Brought to you by 
Novartis, Infinity team up for cancer collaboration
11 Aug 2008
Executive Summary
Expanding upon their original January 2005 deal, Infinity Pharmaceuticals (developing cancer therapeutics) and Novartis will work on the discovery, development, and marketing of drugs that target the Bcl-2 protein family (including Bcl-2 and Bcl-xL) to treat cancer, including hematological cancers and solid tumors.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis, Infinity team up for cancer collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice